Milsaperidone: Side Effects, Uses & Monitoring

BYSANTI™ is indicated for the: Treatment of schizophrenia in adults [see Clinical Studies (14.1) ] .

Data source
FDA labeling via NIH DailyMed (label 254a1c01…)
Label version
current
Last reviewed
2026
Side effects

Reported adverse reactions

Reactions listed in current FDA labeling, with the highest frequency reported across summarized placebo-controlled trials.

No structured frequency data available in current labeling. Consult the official label.

Uses

Labeled uses (from FDA prescribing information)

BYSANTI™ is indicated for the: Treatment of schizophrenia in adults [see Clinical Studies (14.1) ] . Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults [see Clinical Studies (14.2) ] .

FAQ

Frequently Asked Questions

What is Milsaperidone used for?

FDA labeling lists the approved uses shown above under "Labeled uses." This summary is informational; only a qualified prescriber can determine whether a medication is appropriate for you.

What are the most commonly reported side effects of Milsaperidone?

Current labeling for this ingredient does not include a structured frequency table that we can reproduce. Review the official label linked below.

Does Milsaperidone require lab monitoring?

Monitoring needs vary. Ask your healthcare provider whether any lab tests apply while taking Milsaperidone.

Where does this information come from?

All clinical facts on this page were extracted from the current FDA-registered product labeling for this ingredient, published by manufacturers through NIH DailyMed. See the source link below.

Medical disclaimer: Educational content extracted from public FDA labeling. Not medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.

Educational content only: The information on Symptom Database.com is for educational purposes and is not medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider. Read our full disclaimer.